v3.26.1
Note 2 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Revenues $ 60,138 $ 59,543
Consumables [Member] | Transferred at Point in Time [Member]    
Revenues 34,777 35,773
Hardware and Software [Member] | Transferred at Point in Time [Member]    
Revenues 14,125 12,569
Service [Member] | Transferred at Point in Time [Member]    
Revenues 11,236 11,201
Operating Segments [Member] | Sterilization and Disinfection Control [Member]    
Revenues [1],[2],[3] 24,505 25,410
Operating Segments [Member] | Biopharmaceutical Development [Member]    
Revenues [1],[2] 12,059 11,486
Operating Segments [Member] | Calibration Solutions [Member]    
Revenues [1],[2] 13,285 12,350
Operating Segments [Member] | Clinical Genomics [Member]    
Revenues [1],[2] 10,289 10,297
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues [3] 21,925 23,011
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 4,303 3,836
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 810 841
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 7,739 8,085
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues [3] 96 89
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 4,898 4,288
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 7,681 6,975
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 1,450 1,217
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues [3] 2,484 2,310
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 2,858 3,362
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 4,794 4,534
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues $ 1,100 $ 995
[1] Intersegment revenues are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Intersegment revenues are eliminated to arrive at consolidated totals. Revenues as presented are consistent with U.S. GAAP measurement principles and our CODM's review of segment information.
[3] Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales of consumables made beginning from the acquisition date.